Dr. Michael Wang
Radiology (Diagnostic Radiology Physician)
353 W 9th Ave
Escondido, CA 92025
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2010
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Radiology Physician primary
CA license 137558
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $801,238 in research payments for these studies, mostly to the institutions running them.
- A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT02028455 - Tafasitamab, lenalidomide and venetoclax for relapsed/refractory mantle cell lymphoma: A phase 2 study with safety run-in
AbbVie Inc. - A22-935;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets
AbbVie Inc. - A Phase I/II Window Study of Ibrutinibnib Plus Rituximab followed by Venetoclax or Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma the Window II Trial
AbbVie Inc. - A22-935;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.